← Search another drug
PatientPulse · by PatientPartner
Crestor rosuvastatin
High confidence
~59 public patient conversations, reviews, and forum threads referenced; sentiment estimates reflect analyzed corpus tone, not a web-wide tally.
Executive intelligence
The signal that moves starts & adherence
28%Positive sentiment in discussion
198,883FDA adverse-event reports
68%Flagged serious
53%Reports name female patients
Muscle pain is the single biggest adherence killer for Crestor: patients who feel dismissed by their prescriber are the highest churn risk, and peer-validated CoQ10 tips plus dose-titration stories are the conversations that keep them on therapy.
- Muscle pain (myalgia, cramps, weakness) dominates patient discourse and is the primary driver of self-discontinuation, yet patients report their concerns are routinely minimized or denied by prescribing physicians.
- Crestor earns genuine loyalty among tolerant patients for potent LDL reduction, with many describing cholesterol drops of 50-100 points as life-changing validation of the cardiovascular risk argument.
- A significant and growing patient signal links Crestor to neurological and mental-health symptoms (memory loss, anxiety, depression) that are not prominently featured in label copy, creating an information gap and trust deficit.
- The generic-vs-brand potency debate is uniquely active for rosuvastatin, with multiple patients reporting measurable LDL deterioration after switching to generic, representing a concrete adherence and satisfaction risk for the brand.